Q/C Technologies, Inc. Impairment of Intangible Assets, Finite-lived
Q/C Technologies, Inc. (QCLS) reported Impairment of Intangible Assets, Finite-lived of $1.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-04-15
- Q/C Technologies, Inc. impairment of intangible assets, finite-lived for the quarter ending 2018-12-31 was -$2.18M.
- Q/C Technologies, Inc. impairment of intangible assets, finite-lived for the quarter ending 2018-09-30 was $42.78K.
- Q/C Technologies, Inc. impairment of intangible assets, finite-lived for the quarter ending 2015-12-31 was -$1.69M.
- Q/C Technologies, Inc. impairment of intangible assets, finite-lived for the quarter ending 2015-09-30 was $466.48K.
- Q/C Technologies, Inc. impairment of intangible assets, finite-lived for fiscal 2025 was $1.50M.
- Q/C Technologies, Inc. impairment of intangible assets, finite-lived for fiscal 2019 was $32.98K, a 95.39% decline from fiscal 2018.
- Q/C Technologies, Inc. impairment of intangible assets, finite-lived for fiscal 2018 was $716.15K.
- Q/C Technologies, Inc. impairment of intangible assets, finite-lived for fiscal 2015 was -$1.22M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 9 month as first filed | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $1.50M 10-K · filed 2026-04-15 | ||||
| 2019-12-31 | $32.98K 10-K · filed 2020-03-25 | ||||
| 2018-12-31 | -$2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | -$2.14M derived: sum of 2 quarters · filed 2020-03-25 | $716.15K 10-K · filed 2020-03-25 | ||
| 2018-09-30 | $42.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $2.90M 10-Q · filed 2018-11-14 | |||
| 2018-06-30 | $2.85M 10-Q · filed 2018-08-14 | ||||
| 2015-12-31 | -$1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$1.22M derived: sum of 2 quarters · filed 2016-11-14 | -$1.22M 10-K · filed 2016-03-30 | ||
| 2015-09-30 | $466.48K 10-Q · filed 2016-11-14 | $466.48K 10-Q · filed 2016-11-14 | -$466.48K 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |